Journal profile · ONCOLOGY
Oncology and Therapy
ISSN 2366-1070 · eISSN 2366-1089 · Adis, Springer Healthcare · United Kingdom · 2 issues per year
Oncology and Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.4 (journal website); fully open access; APC about USD 7,675; median 64 days to acceptance (89 articles, last 24 months); 88 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Oncology and Therapy is published by Adis, Springer Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers and Cancer survivorship and care, together about 22.8% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Aims and Scope Oncology and Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Oncology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal aims for a 2-week peer review and 3-4 weeks from acceptance to online. Please note that for any steps outside of our standard publication processes, such as multiple rounds of peer review or article proofs, or non-standard copyright requests, this may delay publication beyond these timelines. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts conform to the journal's submission guidelines to ensure the publication of ethically sound and transpar
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Kenrick NgPublisher website
Editorial board by country: 2 in mainland China (about 2%); most named United States 27, Italy 23, United Kingdom 12, Germany 5, Spain 5 (97 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine9.2%
- Cancer Immunotherapy and BiomarkersMedicine8.5%
- Cancer survivorship and careMedicine5.2%
- HER2/EGFR in Cancer ResearchMedicine5%
- Multiple Myeloma Research and TreatmentsMedicine4.7%
- Lung Cancer Research StudiesMedicine4.7%
- Advanced Breast Cancer TherapiesMedicine4.7%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 3.4Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.6Publisher website ·
- CiteScore 2026-06
- 4.4LetPub ·
- SJR 2026-06
- 1.16LetPub ·
- SNIP 2026-06
- 0.96LetPub ·
- h-index
- 33OpenAlex ·
- i10-index
- 107OpenAlex ·
- 2-year mean citedness
- 2.52OpenAlex ·
- Self-citation rate
- 2.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 70LetPub ·
- Downloads per year (publisher) 2025
- 426,900Publisher website ·
Articles by year OpenAlex count · 423 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 53 | 53 | 30 |
| 2025 | 88 | 88 | 181 |
| 2024 | 64 | 64 | 306 |
| 2023 | 38 | 38 | 362 |
| 2022 | 36 | 36 | 496 |
| 2021 | 45 | 45 | 1,039 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
64 daysMedian, submission to acceptance · P25–P75 47 days – 97 days
- Acceptance to online
- median 24 days (89 articles)
- Submission to online
- median 88 days
- Sample
- 89 articles with submission and acceptance dates (158 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Submission to first decision
- 5 daysPublisher website ·
- Acceptance to publication
- 28 daysPublisher website ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 5,950 / USD 7,675 / GBP 5,120 | Yes | CC BY-NC | |
| OpenAlex | USD 7,400 / EUR 5,750 / GBP 4,900 | — | — | |
| LetPub | GBP 4,700 / USD 6,850 / EUR 5,500 | Yes | — | |
| Publisher website | EUR 5,950 / USD 7,675 / GBP 5,120 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteLicense & copyright, Open access, Peer review, Preprints
- License & copyright Copyright
Oncology and Therapy's content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information …
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Oncology and Therapy, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·- Peer review Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and…
Source ↗Publisher website ·- Preprints Preprints
We encourage posting of preprints of primary research manuscripts on preprint servers, authors' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Adis, Springer Healthcare
- Country or region
- United Kingdom
- Language
- English
- Frequency
- 2 issues per year
- ISSN
- 2366-1070
- Electronic ISSN
- 2366-1089
- Latest issue on the website
- Volume 14, Issue 3 (September 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Oncology and Therapy
What CAS zone is Oncology and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Oncology and Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Oncology and Therapy?
The journal's website gives an impact factor of 3.4 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.4, h-index 33.
How long does peer review take at Oncology and Therapy?
Based on the dates recorded on 89 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 64 days (interquartile range 47–97 days); authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Oncology and Therapy based?
Of the 97 board members whose country the journal's board page names, 2 (about 2%) are in mainland China; the countries named most often are United States (27), Italy (23) and United Kingdom (12). Counted from the institutions listed on the board page; for reference only.
Which databases index Oncology and Therapy?
According to LetPub and DOAJ records, Oncology and Therapy is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Embase; that list has not been checked against each database.
Is Oncology and Therapy open access, and what is the APC?
Oncology and Therapy is a fully open-access journal. APC about USD 7,675.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .